Format

Send to

Choose Destination
FASEB J. 2017 Apr;31(4):1547-1555. doi: 10.1096/fj.201600735R. Epub 2017 Jan 9.

LPA1 receptor-mediated thromboxane A2 release is responsible for lysophosphatidic acid-induced vascular smooth muscle contraction.

Author information

1
Institute of Clinical Experimental Research, Semmelweis University, Budapest, Hungary.
2
Department of Physiology, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
3
Institute of Clinical Pharmacology, Goethe University, Frankfurt, Germany.
4
Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
5
Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA; and.
6
Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
7
Department of Physiology, University of Tennessee Health Science Center, Memphis, Tennessee, USA; gtigyi@uthsc.edu.
8
Institute of Clinical Experimental Research, Semmelweis University, Budapest, Hungary; benyo.zoltan@med.semmelweis-univ.hu.

Abstract

Lysophosphatidic acid (LPA) has been recognized recently as an endothelium-dependent vasodilator, but several lines of evidence indicate that it may also stimulate vascular smooth muscle cells (VSMCs), thereby contributing to vasoregulation and remodeling. In the present study, mRNA expression of all 6 LPA receptor genes was detected in murine aortic VSMCs, with the highest levels of LPA1, LPA2, LPA4, and LPA6 In endothelium-denuded thoracic aorta (TA) and abdominal aorta (AA) segments, 1-oleoyl-LPA and the LPA1-3 agonist VPC31143 induced dose-dependent vasoconstriction. VPC31143-induced AA contraction was sensitive to pertussis toxin (PTX), the LPA1&3 antagonist Ki16425, and genetic deletion of LPA1 but not that of LPA2 or inhibition of LPA3, by diacylglycerol pyrophosphate. Surprisingly, vasoconstriction was also diminished in vessels lacking cyclooxygenase-1 [COX1 knockout (KO)] or the thromboxane prostanoid (TP) receptor (TP KO). VPC31143 increased thromboxane A2 (TXA2) release from TA of wild-type, TP-KO, and LPA2-KO mice but not from LPA1-KO or COX1-KO mice, and PTX blocked this effect. Our findings indicate that LPA causes vasoconstriction in VSMCs, mediated by LPA1-, Gi-, and COX1-dependent autocrine/paracrine TXA2 release and consequent TP activation. We propose that this new-found interaction between the LPA/LPA1 and TXA2/TP pathways plays significant roles in vasoregulation, hemostasis, thrombosis, and vascular remodeling.-Dancs, P. T., Ruisanchez, E., Balogh, A., Panta, C. R., Miklós, Z., Nüsing, R. M., Aoki, J., Chun, J., Offermanns, S., Tigyi, G., Benyó, Z. LPA1 receptor-mediated thromboxane A2 release is responsible for lysophosphatidic acid-induced vascular smooth muscle contraction.

KEYWORDS:

LPA; TP receptor; endothelial dysfunction; platelet activation; vasoconstriction

PMID:
28069828
PMCID:
PMC5349804
DOI:
10.1096/fj.201600735R
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center